Arcturus Therapeutics (ARCT) closed the last trading session at $10.84, gaining 5.2% over the past four weeks, but there ...

In CF, Arcturus is advancing an inhalable mRNA therapy, ARCT-032, for which it is running a Phase II trial in patients who ...

Q1 2025 Management View Joe Payne, President and CEO, highlighted heightened interest in the company's mRNA therapeutics pipeline, pointing to forthcoming clinical data for both the ARCT-032 cystic ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Arcturus sets up cameras around the edges of baseball stadiums to capture real-time action and generate a 3D digital clone of the game.

Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 67.09% and 3.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO (AP) — SAN DIEGO (AP) — Arcturus Therapeutics (ARCT) on Monday reported a loss of $14.1 million in its first quarter. On a per-share basis, the San Diego-based company said it had a loss of ...

OK, I admit I may not remember where my car is parked, but I sure recall my grade school planetarium field trips like they just occurred. These were some ...

I remember he said, “Just follow this arc toward Arcturus … then speed on to Spica.” Well, that was pretty cool, and that evening, I was able to do exactly that. Equally fun, though ...

The constellations overhead in May are dominated by Leo the Lion and Ursa Major the Great Bear. Leo is easy to pick out by spotting a large backward question mark known as the Sickle. The bright star ...

Neda Safarzadeh Safarzadeh; Vice President and Head of Investor Relations, Public Relations and Marketing; Arcturus Therapeutics Holdings Inc. Joseph Payne; Presiden ...